Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sounds like you will prevail.
BOL
I wish you ALL the luck in the world with the custody issue!!!
I'm doing great. Cutting stones....must have rocks in my head.
Still long on OPK and ROX.
Hey J nice to hear from you.
Frost 10% insider
http://openinsider.com/search?q=lts
Trading Information
Stock Price History
Beta: 1.71
52-Week Change3: 44.98%
S&P500 52-Week Change3: 14.22%
52-Week High (Oct 9, 2014)3: 4.50
52-Week Low (May 5, 2014)3: 2.57
50-Day Moving Average3: 3.92
200-Day Moving Average3: 3.86
Share Statistics
Avg Vol (3 month)3: 335,646
Avg Vol (10 day)3: 143,257
Shares Outstanding5: 185.33M
Float: 47.78M
% Held by Insiders1: 45.25%
% Held by Institutions1: 12.10%
Shares Short (as of Jan 30, 2015)3: 6.15M
Short Ratio (as of Jan 30, 2015)3: 19.50
Short % of Float (as of Jan 30, 2015)3: 6.20%
Shares Short (prior month)3: 5.56M
Frost 10% insider
http://openinsider.com/search?q=lts
Trading Information
Stock Price History
Beta: 1.71
52-Week Change3: 44.98%
S&P500 52-Week Change3: 14.22%
52-Week High (Oct 9, 2014)3: 4.50
52-Week Low (May 5, 2014)3: 2.57
50-Day Moving Average3: 3.92
200-Day Moving Average3: 3.86
Share Statistics
Avg Vol (3 month)3: 335,646
Avg Vol (10 day)3: 143,257
Shares Outstanding5: 185.33M
Float: 47.78M
% Held by Insiders1: 45.25%
% Held by Institutions1: 12.10%
Shares Short (as of Jan 30, 2015)3: 6.15M
Short Ratio (as of Jan 30, 2015)3: 19.50
Short % of Float (as of Jan 30, 2015)3: 6.20%
Shares Short (prior month)3: 5.56M
Nice find!
It's alive!? Been dead for sooooooooo long.
Its anyone's guess at this time, but with everything that's in the pipeline it is exciting to say the least.
Enjoying the ride.
You're welcome. Nice action today!
Yes
OPKO website with a list of press releases.
http://investor.opko.com/releases.cfm
A definite maybe.
Man I'm sounding like a politician now.
Some,
Perhaps they felt no rush back then. Still waiting for the NDA to be filed. Just saying that might be the catalyst.
Regardless I am enjoying the ride.
I'm sure I know less than most ( I am a married man, so I am automatically wrong), but could this be the reason for the rise in volume, etc.
http://investor.opko.com/releases.cfm
September 23, 2014
OPKO's Second Rayaldee Phase 3 Trial Meets Primary Endpoints
Targeted Response Rate Achieved for Plasma Parathyroid Hormone Reduction
Favorable Adverse Event Profile Consistent with First Phase 3 Trial
New Drug Application Submission to U.S. FDA Planned for End of 2014
MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (NYSE: OPK), announced successful top-line results from the second and final pivotal phase 3 trial of Rayaldee™. This trial is the second of two identical randomized, double-blind, placebo-controlled, multi-site studies intended to establish the safety and efficacy of Rayaldee as a new treatment for secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. Both trials are the subject of a Special Protocol Assessment established with the United States (U.S.) Food and Drug Administration (FDA) in August 2012.
"Top-line data from this second study confirmed that Rayaldee effectively controls secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease by correcting vitamin D insufficiency," stated Joel Z. Melnick, M.D., Vice President of Clinical Research and Development for OPKO's Renal Division. "As with the first trial, Rayaldee was equally effective in both disease stages, indicating that this new therapy is appropriate even for patients with minimal functioning kidney mass."
This trial involved 216 adult patients recruited from 38 sites throughout the U.S. Patients were stratified by CKD stage and randomized in a 2:1 fashion to receive six months of treatment with either Rayaldee or placebo. On enrollment, all patients exhibited vitamin D insufficiency which was corrected in 96% of patients treated with Rayaldee vs. 8% of patients treated with placebo.
The completed trial successfully met all primary efficacy and safety endpoints. The primary efficacy endpoint was a responder analysis in which "responder" was defined as any treated subject who demonstrated an average 30% decrease in plasma parathyroid hormone (PTH) from pre-treatment baseline during the last six weeks of the treatment period. A significantly higher response rate was observed with Rayaldee which steadily increased with treatment duration. The response rate with Rayaldee was similar in CKD stages 3 and 4. Safety and tolerability data were comparable in both treatment groups.
Patients who completed the two pivotal trials are being treated, at their election, for an additional 6 months with Rayaldee during an open-label extension study. Enrollment in this extension study is complete at 298 patients, of which 180 (69%) patients have completed participation.
"The data from the two pivotal phase 3 studies, when combined with the available data from the ongoing open-label extension study, provide a clear picture of Rayaldee's efficacy during longer-term administration," commented Dr. Charles W. Bishop, Ph.D., CEO of OPKO's Renal Division. "The gradual but progressive PTH lowering observed during 6 months of treatment in the pivotal trials is continuing during 6 additional months of treatment in the extension study, allowing PTH levels to return to the normal range in a significant proportion of patients."
"Gradual reduction of elevated PTH towards the normal range is likely to become the new treatment goal for predialysis patients whose secondary hyperparathyroidism has not become firmly established," stated Stuart M. Sprague, DO, Chief, Division of Nephrology and Hypertension, NorthShore University Health System - University of Chicago, Pritzker School of Medicine. "Currently, these patients are treated with high doses of nutritional vitamin D, but fewer than 50% show an adequate response. Inadequate correction of vitamin D insufficiency with nutritional vitamin D allows secondary hyperparathyroidism to become established and less responsive to treatment. The phase 3 data with Rayaldee show that this product is highly effective in correcting vitamin D insufficiency, allowing more reliable treatment of these patients."
"OPKO is committed to improving the care of patients with chronic kidney disease by developing safer and more effective therapies for secondary hyperparathyroidism than those available today," commented Phillip Frost, M.D., Chairman and CEO of OPKO Health. "Rayaldee provides an excellent solution to the problem of secondary hyperparathyroidism associated with vitamin D insufficiency for the 20 million pre-dialysis CKD patients in the U.S. and many more elsewhere."
A New Drug Application submission to the FDA is planned for the end of 2014.
About RayaldeeTM
Rayaldee is a first-in-class oral vitamin D prohormone treatment being developed for SHPT in patients with stage 3 or 4 CKD and vitamin D insufficiency. It has a proprietary modified-release formulation designed to gradually and reliably raise serum total 25-hydroxyvitamin D (prohormone) concentrations to targeted levels (at least 30 ng/mL) while avoiding upregulation of CYP24, a cytochrome P-450 enzyme that reduces the PTH-lowering potency of current vitamin D supplements. Activation of calcifediol, the active ingredient in Rayaldee, by the kidney is tightly regulated, preventing excessive elevation of serum calcium and related side effects which limit the value of current vitamin D hormone therapies by promoting vascular and renal calcification. Rayaldee is expected to address the approximately 8 million patients in the U.S., and many more elsewhere, with stage 3 or 4 CKD, SHPT and vitamin D insufficiency.
About Chronic Kidney Disease
CKD is a condition characterized by a progressive decline in kidney function. The kidney is normally responsible for excreting waste and excess water from the body, and for regulating various hormones. CKD is classified in five different stages — mild (stage 1) to severe (stage 5) disease — as measured by the kidney's glomerular filtration rate. According to the National Kidney Foundation, CKD afflicts over 26 million people in the U.S., including more than 20 million patients with moderate (stages 3 or 4) and severe (stage 5) forms of CKD. In stage 5 CKD, kidney function is minimal to absent and patients require regular dialysis or a kidney transplant for survival.
About Vitamin D Insufficiency
Vitamin D insufficiency is a condition in which the body has low vitamin D stores, characterized by inadequate blood levels of vitamin D prohormone, known as 25-hydroxyvitamin D. An estimated 70-90% of CKD patients have vitamin D insufficiency, which can lead to SHPT and resultant debilitating bone diseases. Vitamin D insufficiency has been associated with increased mortality in CKD.
About Secondary Hyperparathyroidism (SHPT)
SHPT is a condition commonly associated with CKD in which the parathyroid glands secrete excessive amounts of PTH. SHPT arises as a result of vitamin D insufficiency or impaired kidney function that prevents sufficient production of vitamin D hormone to properly regulate calcium and phosphorus metabolism, and PTH secretion. Prolonged elevation of blood PTH causes excessive calcium and phosphorus to be released from bone, leading to elevated serum calcium and phosphorus, softening of the bones (osteomalacia) and calcification of vascular and renal tissues. SHPT affects 40-60% of patients with moderate CKD and approximately 90% of patients with severe CKD. Vitamin D therapy for SHPT is associated with reduced mortality in CKD patients.
About Special Protocol Assessment
The Special Protocol Assessment provided a mechanism for the FDA and OPKO to reach agreement on the design, size, execution and analysis of the two pivotal phase 3 trials with Rayaldee. The FDA agreed that the design and planned analysis of these studies adequately addressed the objectives necessary to support an NDA submission.
About OPKO
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), regarding product development efforts and other non-historical facts about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects, including statements regarding our ability to successfully launch and commercialize proprietary renal disease products, expectations about Rayaldee, that Rayaldee will effectively control secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease by correcting vitamin D insufficiency, whether Rayaldee is appropriate for patients with minimal functioning kidney mass and its efficacy during longer term administration, whether Rayaldee will be highly effective in correcting vitamin D insufficiency, allowing more reliable treatment of patients, whether it is the solution to secondary hyperparathyroidism associated with vitamin D insufficiency for the 20 million pre-dialysis CKD patients in the U.S. and elsewhere, market potential for Rayaldee, that it will address the approximately 4 million CKD stage 3 and 4 patients in the U.S. and many more elsewhere, with SHPT and vitamin D insufficiency, that Rayaldee will treat vitamin D insufficiency and gradually correct elevated PTH, without safety concerns, the expected timing of the NDA submission, and that we will be able to successfully develop, obtain approval for and launch sales of Rayaldee. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that the phase 3 clinical trials for Rayaldee may not generate data that would support the approval or marketing of this product for the indications being studied, that others may develop products which are superior to Rayaldee, and that Rayaldee may not have advantages or prove to be superior over presently marketed products, including the currently used high monthly doses of prescription vitamin D2, activated vitamin D hormone and over-the-counter vitamin D supplements. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
OPKO Health, Inc.
Charles W. Bishop, 305-575-4100
Source: OPKO Health, Inc.
News Provided by Acquire Media
someconcerns,
It's all good, I was just trying to be accurate.
Here's a list of purchases by the other 2 insiders that recently exercised their options.
http://openinsider.com/insider/Hsiao-Jane-Ph-D/1188834
http://openinsider.com/insider/Rubin-Steven-D/1381874
The actual short position is closer to 49 million according to the link.
I agree about not counting my chickens before the eggs hatch, but Frost purchases OPK considerably more ofter than his other holdings.
It might only be a break in the pattern, but with the others exercising their options recently, one can't help but wonder.
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
1/30/2015 48,921,162 3,281,549 14.907948
1/15/2015 47,384,626 2,522,649 18.783678
Read more: http://www.nasdaq.com/symbol/opk/short-interest#ixzz3RZZrIAmn
500 results
SEC Form 4
Trade Date
Ticker
Insider
Title
Shares
Insider Trade
Value
Owned
Held
Feb 4 09:13:12
MFeb 3 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 25,000 Purchase at $12.16 $304,082 154,334,797 indirect
DFeb 4 06:04:46
Feb 3 2015
VGR Frost Phillip Md Et Al 10% Owner 2,227,552 Converted deriv at $0.00 $0 4,455,104 indirect
DFeb 2 06:00:38
MJan 31 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 14,786,430 Option exercise at $0.39 $5,712,275 20,286,704 indirect
DFeb 2 06:00:38
MJan 31 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 906,146 OptEx/tax payment at $11.77 $10,668,216 20,091,062 indirect
Jan 29 08:51:30
MJan 28 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 15,000 Purchase at $11.27 $169,097 145,030,029 indirect
Jan 26 09:28:39
MJan 23 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 10,000 Purchase at $10.84 $108,397 145,015,029 indirect
Jan 23 09:27:47
MJan 22 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 28,000 Purchase at $10.52 $294,581 145,005,029 indirect
Jan 22 07:45:54
MJan 21 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 41,700 Purchase at $10.23 $426,666 144,977,029 indirect
Jan 21 09:26:21
MJan 20 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 45,000 Purchase at $10.11 $455,026 144,935,329 indirect
Jan 20 07:10:53
MJan 16 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 25,000 Purchase at $10.01 $250,193 144,890,329 indirect
Jan 16 08:27:28
MJan 15 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 44,000 Purchase at $10.00 $439,912 144,865,329 indirect
Jan 14 08:42:24
MJan 13 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 25,000 Purchase at $10.15 $253,714 144,821,329 indirect
Jan 12 08:00:32
Jan 9 2015
LTS Frost Phillip Md Et Al Director, 10% Owner 10,000 Purchase at $3.91 $39,149 12,538,699 indirect
Jan 12 07:37:50
MJan 9 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 9,200 Purchase at $10.10 $92,928 144,796,329 indirect
Jan 9 09:54:26
MJan 8 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 22,300 Purchase at $10.03 $223,718 144,787,129 indirect
DJan 7 07:55:28
Jan 6 2015
LTS Frost Phillip Md Et Al Director, 10% Owner 20,000 Option exercise at $0.48 $9,600 20,000 direct
Jan 7 07:24:36
MJan 6 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 26,000 Purchase at $9.92 $257,913 144,764,829 indirect
Jan 5 09:17:35
MJan 2 2015
OPK Frost Phillip Md Et Al CEO, Chairman, 10% Owner 28,000 Purchase at $9.92 $277,715 144,738,829 indirect
Jan 5 08:02:03
Dec 31 2014
LTS Frost Phillip Md Et Al Director, 10% Owner 100,000 Purchase at $4.09 $408,640 12,528,699 indirect
Jan 2 09:23:42
MDec 31 2014
OPK[color=red][/color] Frost
Nice Board! Marked
I hope this helps.
DEFINITION of 'Short Squeeze'
A situation in which a heavily shorted stock or commodity moves sharply higher, forcing more short sellers to close out their short positions and adding to the upward pressure on the stock. A short squeeze implies that short sellers are being squeezed out of their short positions, usually at a loss. A short squeeze is generally triggered by a positive development that suggests the stock may be embarking on a turnaround. Although the turnaround in the stock’s fortunes may only prove to be temporary, few short sellers can afford to risk runaway losses on their short positions and may prefer to close them out even if it means taking a substantial loss.
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
1/30/2015 48,921,162 3,281,549 14.907948
1/15/2015 47,384,626 2,522,649 18.783678
12/31/2014 44,649,975 3,965,457 11.259730
12/15/2014 47,081,387 2,643,665 17.809135
11/28/2014 48,228,252 1,612,780 29.903801
11/14/2014 49,124,942 2,342,350 20.972503
10/31/2014 48,656,793 1,726,510 28.182167
10/15/2014 50,002,380 2,295,303 21.784653
9/30/2014 52,862,060 2,652,506 19.929101
9/15/2014 50,290,416 2,159,230 23.290903
8/29/2014 48,813,921 1,897,770 25.721727
8/15/2014 48,678,134 2,579,771 18.869169
7/31/2014 48,696,939 2,200,828 22.126645
7/15/2014 48,164,118 2,451,899 19.643598
6/30/2014 48,981,522 3,771,645 12.986780
6/13/2014 51,904,149 2,038,550 25.461308
5/30/2014 49,772,804 2,038,463 24.416830
5/15/2014 50,108,039 1,672,892 29.952943
4/30/2014 50,337,366 2,431,204 20.704707
4/15/2014 47,379,151 3,202,956 14.792320
3/31/2014 46,560,772 2,702,363 17.229651
3/14/2014 45,737,994 2,664,173 17.167802
2/28/2014 45,638,714 3,460,345 13.189065
2/14/2014 46,549,197 3,218,603 14.462547
When is short interest updated?
NASDAQ OMX short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then released on a dissemination date after 4 p.m. ET.
Read more: http://www.nasdaq.com/symbol/opk/short-interest#ixzz3RXSDQqSA
What me worry. lol
Still NO recent purchases by Frost!!!!!!!!
Me thinks his silence is a sign.
I hear ya. Could just be a break from his normal pattern. There could still be a filing yet today.
Regardless, BIG volume lately!!!!!!
"I think OPK is the only stock I have ever owned that I like when the CEO... STOPS BUYING SHARES !! LOL "
I couldn't have said it any better!!!!!
Yea, it's been a while since Frost last bought. Hmmmmmmm
Nice increase in pps and volume since the beginning of the year.
13.50 Up 0.03(0.22%) Feb 6, 4:02PM EST
After Hours : 13.71 Up 0.21 (1.56%) Feb 6, 6:55PM EST
Historical Prices
Prices
Date Open High Low Close Volume Adj Close*
Feb 6, 2015 13.47 13.99 13.20 13.50 7,663,100 13.50
Feb 5, 2015 12.96 13.54 12.84 13.47 9,181,300 13.47
Feb 4, 2015 12.35 12.89 12.17 12.77 5,427,900 12.77
Feb 3, 2015 12.70 12.74 11.70 12.35 8,719,500 12.35
Feb 2, 2015 12.13 12.65 12.04 12.63 4,296,300 12.63
Jan 30, 2015 11.89 12.32 11.80 12.13 3,889,400 12.13
Jan 29, 2015 11.71 11.95 11.48 11.86 4,824,200 11.86
Jan 28, 2015 11.48 11.55 11.10 11.34 3,993,500 11.34
Jan 27, 2015 11.24 11.60 11.22 11.38 3,390,800 11.38
Jan 26, 2015 10.92 11.38 10.86 11.37 2,938,700 11.37
Jan 23, 2015 10.61 10.99 10.59 10.84 3,346,400 10.84
Jan 22, 2015 10.36 10.62 10.22 10.61 2,987,900 10.61
Jan 21, 2015 10.25 10.40 10.15 10.29 2,339,400 10.29
Jan 20, 2015 10.10 10.29 9.96 10.24 2,319,700 10.24
Jan 16, 2015 9.93 10.13 9.91 10.02 2,748,200 10.02
Jan 15, 2015 10.33 10.35 9.89 9.97 2,585,400 9.97
Jan 14, 2015 10.20 10.40 10.14 10.30 2,606,500 10.30
Jan 13, 2015 10.27 10.44 10.02 10.19 2,806,500 10.19
Jan 12, 2015 10.14 10.39 10.12 10.27 3,328,200 10.27
Jan 9, 2015 10.09 10.14 10.00 10.10 2,074,600 10.10
Jan 8, 2015 10.15 10.15 9.96 10.06 2,493,200 10.06
Jan 7, 2015 9.99 10.15 9.95 10.09 2,003,400 10.09
Jan 6, 2015 10.09 10.22 9.81 9.91 2,741,300 9.91
Jan 5, 2015 9.90 10.25 9.88 10.06 2,567,600 10.06
Jan 2, 2015 10.03 10.10 9.82 9.93 2,007,000 9.93
Good morning.
WOW is right!!!! imo
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (OPK) today announced the launch of the 4Kscore® test, the only blood test that accurately identifies risk for aggressive prostate cancer, in Mexico through its wholly owned subsidiary, OPKO Health Mexico. The launch in Mexico follows the U.S. and European launch of the 4Kscore test in 2014.
The 4Kscore provides a patient with his own individualized risk for aggressive prostate cancer. The test was developed and validated by OPKO in a 1,012 patient blinded, prospective study in the United States in 2014. The results of this validation trial were published in the journal European Urology and presented at the 2014 Congress of the Mexican Society of Urology by one of the publication’s authors, Dr. Sanoj Punnen, of the University of Miami.
“We are pleased to now be able to offer the 4Kscore test to the clinicians and patients of Mexico,” said Joaquin Peniche, CEO of OPKO Health Mexico. “The plenary presentation on the 4Kscore was well received by Urologists attending the Congress of the Mexican Society of Urology in Guadalajara, Mexico this past November and we now look forward to offering the product into the Mexican market.”
In Mexico, prostate cancer is the most common cause of cancer death in males with 5,911 deaths recorded in 2012.
Frost just keeps buying.
http://openinsider.com/search?q=opk
Good Luck John! I'll be praying for the best.
There are still some out there. Brrrrave souls!
Share Statistics
Avg Vol (3 month)3: 2,532,560
Avg Vol (10 day)3: 2,676,270
Shares Outstanding5: 434.14M
Float: 238.10M
% Held by Insiders1: 51.18%
% Held by Institutions1: 18.50%
Shares Short (as of Dec 31, 2014)3: 44.65M
Short Ratio (as of Dec 31, 2014)3: 13.50
Short % of Float (as of Dec 31, 2014)3: 20.10%
Shares Short (prior month)3: 47.08M
https://finance.yahoo.com/q/ks?s=OPK+Key+Statistics
What I really meant was......................
Really?
It's alive!???